213 related articles for article (PubMed ID: 21132003)
1. Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma.
Morris MR; Ricketts CJ; Gentle D; McRonald F; Carli N; Khalili H; Brown M; Kishida T; Yao M; Banks RE; Clarke N; Latif F; Maher ER
Oncogene; 2011 Mar; 30(12):1390-401. PubMed ID: 21132003
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
3. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Clarke N; Brown M; Kishida T; Yao M; Teh BT; Latif F; Maher ER
Br J Cancer; 2008 Jan; 98(2):496-501. PubMed ID: 18195710
[TBL] [Abstract][Full Text] [Related]
4. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma.
Morris MR; Ricketts C; Gentle D; Abdulrahman M; Clarke N; Brown M; Kishida T; Yao M; Latif F; Maher ER
Oncogene; 2010 Apr; 29(14):2104-17. PubMed ID: 20154727
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma.
Lv D; Zhao W; Dong D; Qian XP; Zhang Y; Tian XJ; Zhang J
Eur J Cancer; 2011 Sep; 47(13):2068-76. PubMed ID: 21600761
[TBL] [Abstract][Full Text] [Related]
6. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
7. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
[TBL] [Abstract][Full Text] [Related]
8. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
[TBL] [Abstract][Full Text] [Related]
10. Classic SRY-box protein SOX7 functions as a tumor suppressor regulating WNT signaling and is methylated in renal cell carcinoma.
Wang L; Fan Y; Zhang L; Li L; Kuang G; Luo C; Li C; Xiang T; Tao Q; Zhang Q; Ying J
FASEB J; 2019 Jan; 33(1):254-263. PubMed ID: 29957056
[TBL] [Abstract][Full Text] [Related]
11. OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma.
Zhang Y; Yuan Y; Liang P; Guo X; Ying Y; Shu XS; Gao M; Cheng Y
Oncotarget; 2017 May; 8(18):30008-30018. PubMed ID: 28404905
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.
Wang L; Cui Y; Sheng J; Yang Y; Kuang G; Fan Y; Jin J; Zhang Q
Oncotarget; 2017 Mar; 8(13):21861-21870. PubMed ID: 28423531
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma.
Ricketts CJ; Morris MR; Gentle D; Brown M; Wake N; Woodward ER; Clarke N; Latif F; Maher ER
Epigenetics; 2012 Mar; 7(3):278-90. PubMed ID: 22430804
[TBL] [Abstract][Full Text] [Related]
15. Multigene methylation analysis of conventional renal cell carcinoma.
Onay H; Pehlivan S; Koyuncuoglu M; Kirkali Z; Ozkinay F
Urol Int; 2009; 83(1):107-12. PubMed ID: 19641369
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma.
Zhao T; Bao Y; Gan X; Wang J; Chen Q; Dai Z; Liu B; Wang A; Sun S; Yang F; Wang L
Theranostics; 2019; 9(21):6175-6190. PubMed ID: 31534544
[No Abstract] [Full Text] [Related]
17. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.
Morris MR; Hesson LB; Wagner KJ; Morgan NV; Astuti D; Lees RD; Cooper WN; Lee J; Gentle D; Macdonald F; Kishida T; Grundy R; Yao M; Latif F; Maher ER
Oncogene; 2003 Oct; 22(43):6794-801. PubMed ID: 14555992
[TBL] [Abstract][Full Text] [Related]
18. The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features.
Wang L; Cui Y; Zhang L; Sheng J; Yang Y; Kuang G; Fan Y; Zhang Q; Jin J
PLoS One; 2016; 11(9):e0161859. PubMed ID: 27583477
[TBL] [Abstract][Full Text] [Related]
19. Methylation-associated silencing of TU3A in human cancers.
Awakura Y; Nakamura E; Ito N; Kamoto T; Ogawa O
Int J Oncol; 2008 Oct; 33(4):893-9. PubMed ID: 18813805
[TBL] [Abstract][Full Text] [Related]
20. RASSF1A promoter methylation and expression analysis in normal and neoplastic kidney indicates a role in early tumorigenesis.
Peters I; Rehmet K; Wilke N; Kuczyk MA; Hennenlotter J; Eilers T; Machtens S; Jonas U; Serth J
Mol Cancer; 2007 Jul; 6():49. PubMed ID: 17634119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
